References
- Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37–51
- Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996; 1: 275–284
- Rosenberg M J, Long S C. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 1992; 8(Suppl 1)35–45
- Oelkers W K. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids 1996; 61: 166–171
- Foidart J M. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5(Suppl 3)25–33
- Huber J, Foidart J M, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34
- van Seumeren. Weight gain and hormone replacement therapy: are women's fears justified?. Maturitas 2000; 34(Suppl 1)S3–S8
- Strothmann A, Schneider H P. Hormone therapy: the European women's perspective. Climacteric 2003; 6: 337–346
- Archer D F, Thorneycroft I H, Foegh M, et al. Efficacy and safety of drospirenone-estradiol for hormone therapy: a randomized multicenter trial. Menopause 2005, in press
- Freeman E W, Kroll R, Rapkin A, et al. Evaluationof a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561–569
- Barnhart K T, Freeman E W, Sondheimer S J. A clinician's guide to the premenstrual syndrome. Med Clin North Am 1995; 79: 1457–1472
- Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000; 61(Suppl 12)17–21
- Freeman E W. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3)27–34, discussion 42–3
- Endicott J, Amsterdam J, Eriksson E, et al. Ispremenstrual dysphoric disorder a distinct clinical entity?. J Womens Health Gend Based Med 1999; 8: 663–679
- Warner P, Bancroft J. Factors related to self-reporting of the pre-menstrual syndrome. Br J Psychiatry 1990; 157: 249–260
- Harding C M, Vail C, Brown R. Effect of oral contraceptives and some psychological factors on the menstrual experience. J Biosoc Sci 1985; 17: 291–304
- Graham C A, Sherwin B B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257–266
- Backstrom T, Hansson-Malmstrom Y, Lindhe B A, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46: 253–268
- Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and othersymptoms. J Psychosom Res 1993; 37: 195–202
- Graham C A, Sherwin B B. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res 1987; 31: 45–53
- Marriott A, Faragher E B. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res 1986; 30: 41–47
- Borenstein J, Yu H T, Wade S, Chiou C F, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003; 48: 79–85
- Parsey K S, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105–111
- Hunter M S. The Women's Health Questionnaire (WHQ): frequently asked questions (FAQ). Health Qual Life Outcomes 2003; 1: 41